Pulse Biosciences Grants Equity Inducement Awards to New Employees
December 15 2017 - 8:32PM
Business Wire
Pulse Biosciences, Inc. (NASDAQ: PLSE), a medical technology
company developing a proprietary therapeutic tissue treatment based
on its Nano-Pulse Stimulation (NPS) platform, today announced that
the Compensation Committee of the company’s Board of Directors
granted non-qualified stock options to purchase an aggregate of
121,000 shares of Pulse Biosciences common stock to seven (7) new
employees under Pulse Biosciences, Inc. 2017 Inducement Equity
Incentive Award Plan.
The 2017 plan is used exclusively to grant equity awards to
individuals who were not previously an employee or non-employee
director of Pulse Biosciences as an inducement material to such
individual's entering into employment with Pulse Biosciences in
accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of $24.78 per share, which is
equal to the closing price of Pulse Biosciences common stock on
December 15, 2017. Each option will vest and become exercisable as
to 25% of the shares on the first anniversary of the recipient’s
start date, and will vest and become exercisable as to the
remaining 75% of the shares in 36 equal monthly installments
following the first anniversary, subject to each employee’s
continued employment with Pulse Biosciences on these vesting dates.
The options are subject to the terms and conditions of Pulse
Bioscience’s 2017 Employment Inducement Equity Incentive Award
Plan, and the award agreements entered into with each
recipient.
About Pulse Biosciences
Pulse Biosciences is a medical technology company developing a
therapeutic tissue treatment platform based on Nano-Pulse
Stimulation (NPS), a proprietary high-speed cell signaling
technology. NPS is a non-thermal, precise, focal drug-free tissue
treatment technology that directly affects the cell membrane and
intracellular structures to stimulate unique behaviors in cells.
NPS can initiate a cell death process. That process provides a
means for the treatment of tissue cells with minimal inflammatory
response. This has the potential to improve healing outcomes. This
process may also contribute to the replacement of treated tissue
cells with healthy new tissue cells. In cancerous lesions, NPS has
been shown in preclinical models to induce immunogenic cell death
(ICD) exposing the unique antigens of the treated cells to the
immune system, resulting in the generation of cytotoxic T-cells and
the mounting of an adaptive immune response targeted against those
cells. Pulse Biosciences is investigating a variety of applications
for its technology that exploits the technology’s unique biologic
effect. More information is available at
www.pulsebiosciences.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171215005884/en/
Pulse Biosciences, Inc.Investors:Brian DowSr. Vice
President and Chief Financial OfficerIR@pulsebiosciences.comorThe
Trout GroupMike Zanoni,
646-378-2924mzanoni@troutgroup.comorMedia:Sam Brown, Inc.Christy
Curran, 615-414-8668christycurran@sambrown.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024